Pilot Imaging Study With 89Zr-Trastuzumab in HER2-positive Metastatic Breast Cancer Patients
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Neoplasms|Secondary|HER2 Positive Carcinoma of Breast
Interventions: DRUG: Zr89-trastuzumab
Sponsor: Jules Bordet Institute